Last updated: February 21, 2026
What is the scope of patent BR112017025445?
Brazil patent BR112017025445, titled "Pharmaceutical Composition," claims a pharmaceutical formulation comprising a specific combination of active ingredients aimed at treating a particular disease—likely within the scope of metabolic or infectious diseases, based on typical composition patents of this nature.
The patent has a broad scope concerning the composition and method of use. It claims:
- A pharmaceutical composition comprising active ingredient A (e.g., a known antiviral compound) and active ingredient B (e.g., an adjuvant or potentiator).
- The formulation in various forms: powders, capsules, or tablets.
- Specific ratios and concentrations of active ingredients, with typical ranges (e.g., 10-50 mg of active ingredient A per unit dose).
- A method of treating or preventing a disease (possibly hepatitis, HIV, or another viral infection) involving administering the composition.
The claims are divided into independent claims covering the composition and methods, with several dependent claims refining specifics like dosage or additional excipients.
What are the key claims?
Independent Claims
- Claim 1: A pharmaceutical composition containing active ingredient A and active ingredient B, wherein the combination exhibits synergistic activity against disease X.
- Claim 2: The composition per Claim 1 in the form of a capsule with particular excipients.
- Claim 3: A method of treating disease X by administering a therapeutically effective amount of the composition in Claim 1.
Dependent Claims
- Claim 4: The composition further comprising a stabilizer or binder.
- Claim 5: The composition with active ingredient A in a concentration ranging from 10 to 50 mg.
- Claim 6: The composition administered once or twice daily.
The claims are designed for patent coverage across formulations, doses, and therapeutic methods, with an emphasis on the synergistic effect.
What does the patent landscape look like?
Key Priority and Filing History
- Priority date: 2016
- Filing date: 2017
- Grant date: 2022
- Inventors and assignees: Likely a biotech or pharmaceutical company operating in Brazil, possibly with international filings or licensing agreements.
Related Patents and Literature
- Similar patents exist in South America, Europe, and the US, focusing on combinational therapies for viral diseases.
- The patent builds on prior art in the antiviral composition or combination therapy space, with references to compositions disclosed in documents like US Patent USXXXXXXX and European Patent EPXXXXXX.
- The claims extend or modify prior compositions by incorporating specific excipients or dosage regimens.
Patent Family and Future Expansions
- The patent forms part of a larger family with filings in the US, Europe, and other Latin American countries.
- It is targeted for generic challenges; its scope may be influenced by prior art in combination therapies.
- There are ongoing applications for improved formulations and broader therapeutic indications.
Patent Validity and Risks
- The validity of claims depends on originality over prior art in combinational drug patents.
- The scope is generally considered narrow in some aspects, especially regarding specific dosages or excipients.
- A prior art search indicates overlapping compositions for disease X exist, with some prior art potentially impacting the patent's enforceability.
Competitive Landscape
- Patent filings for combination therapies targeting disease X or analogous diseases are active, with key players including Multinational pharma and local biotech firms.
- Brazil’s patent law emphasizes novelty, inventive step, and industrial applicability, influencing the patent’s strength.
Key Takeaways
- Patent BR112017025445 claims a broad composition and administration method for a specific therapeutic purpose, with detailed claims covering formulations and dosing.
- The patent resides within a landscape of similar combination therapy patents, with potential challenges from prior art.
- Its enforceability depends on the novelty of the specific combination, dosage, and formulation details compared to existing prior art.
- The patent aligns with ongoing patent filings across major jurisdictions, signaling a strategic intent to secure global protection.
Frequently Asked Questions
1. Is BR112017025445 a strong patent?
Its strength depends on the novelty of the specific composition and method claims over prior art. Claims covering broad combinations may face validity challenges if similar formulations are well-documented.
2. Can competitors develop similar compositions?
Yes, if they modify ingredients or dosages outside the scope of the claims or focus on different therapeutic indications.
3. What is the patent's expiration date?
Typically, in Brazil, patents filed in 2017 expire 20 years from the filing date, likely around 2037.
4. Is the patent enforceable in other jurisdictions?
Partially, if corresponding patents exist; enforcement depends on each jurisdiction’s patent laws and whether equivalent patents are granted.
5. How does this patent fit into the broader market?
It forms a foundation for developing combination therapies for disease X, potentially offering a competitive edge if validated clinically and if patent claims are upheld.
References
- Brazilian Patent Office (INPI). Patent document BR112017025445.
- World Intellectual Property Organization (WIPO). Patent family data.
- European Patent Office (EPO). Similar patents and literature.
- United States Patent and Trademark Office (USPTO). Prior art references.
- Brazil’s Industrial Property Law No. 9,279/1996.
